09.27.17
Selexis SA and OSE Immunotherapeutics SA have signed two commercial license agreements (CLAs) that provide OSE with access to high-performance research Cell banks (RCBs) developed using the Selexis SUREtechnology Platform. The agreements are designed to support the advancement of the clinical development of OSE-172 (Effi-DEM), OSE’s new generation immune myeloid checkpoint inhibitor, as well as OSE-703 (Effi-3), OSE’s cancer immunotherapy, which is a Cytotoxic monoclonal Antibody targeting the IL-7 Receptor .
“This is our third signed CLA with OSE this year, and we believe the rapid expansion of our relationship is a direct result of the utility and flexibility of our cell-line Expression technology across Protein Therapeutics and development stages,” said Marco Bocci, vice president, licensing and business development, Selexis. “One of the most fulfilling aspects of our work at Selexis is that we are able to play a role in our partners’ success, which means the possibility of new therapeutic options for patients with many life-threatening diseases. Selexis’ technology can scale with OSE’s developmental needs, and provide the company with a fast, stable and reliable method of protein expression. This is critical for the development of recombinant, protein-based medicines like OSE-172 and OSE-703.”
Alexis Peyroles, chief operating officer, OSE Immunotherapeutics, said, “Our work with Selexis has been instrumental in advancing our investigational therapeutic candidates toward clinical development. OSE and Selexis are focused on quickly advancing delivery of treatment options to patients facing life-threatening diseases. It’s exciting to watch the evolution of our relationship with Selexis, knowing the impact their technology is having on our research and development activities.”
Selexis’ proprietary SUREtechnology Platform facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the biologics development continuum, spanning discovery to commercialization.
“This is our third signed CLA with OSE this year, and we believe the rapid expansion of our relationship is a direct result of the utility and flexibility of our cell-line Expression technology across Protein Therapeutics and development stages,” said Marco Bocci, vice president, licensing and business development, Selexis. “One of the most fulfilling aspects of our work at Selexis is that we are able to play a role in our partners’ success, which means the possibility of new therapeutic options for patients with many life-threatening diseases. Selexis’ technology can scale with OSE’s developmental needs, and provide the company with a fast, stable and reliable method of protein expression. This is critical for the development of recombinant, protein-based medicines like OSE-172 and OSE-703.”
Alexis Peyroles, chief operating officer, OSE Immunotherapeutics, said, “Our work with Selexis has been instrumental in advancing our investigational therapeutic candidates toward clinical development. OSE and Selexis are focused on quickly advancing delivery of treatment options to patients facing life-threatening diseases. It’s exciting to watch the evolution of our relationship with Selexis, knowing the impact their technology is having on our research and development activities.”
Selexis’ proprietary SUREtechnology Platform facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the biologics development continuum, spanning discovery to commercialization.
